Phase 3 Randomized, Controlled Study of Blinatumomab Alternating with Low-intensity Chemotherapy Versus Standard of Care for Older Adults with Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia with Safety Run-in (Golden Gate Study)